| |
Practice Areas:
Patent Prosecution: Biotechnology
and Chemistry
Summary of Practice:
Robert Traver is a patent attorney with experience
in the general areas of chemistry, pharmaceuticals and biotechnology.
His practice areas of emphasis include licensing, opinions,
due diligence and all aspects of domestic and foreign patent
prosecution in chemistry, biochemistry, pharmaceuticals, nutraceuticals,
therapeutic methods, diagnostic methods and polymer chemistry.
Prior to joining Sheridan Ross, Robert conducted toxicological
and molecular research on phase II metabolism and cancer,
as well as testing of anti-cancer compounds.
Bar Admissions:
Colorado, 2000
United States Federal District Court, Colorado, 2000
United States Patent and Trademark Office, 2001
Education:
| University of Colorado (B.S.,
Pharmacy, with honors, 1988) |
| University of Southern California
(Ph.D., Pharmaceutical Sciences, 1997) |
| |
• |
|
All University Predoctoral
Merit Fellowship, 1989-1991, |
| |
• |
|
Pharmaceutical Manufacturers Association,
Advanced Predoctoral Fellow,
Pharmacology/Toxicology, 1992. |
| University of Colorado (J.D.,
2000) |
| |
• |
|
Managing Editor, University of Colorado
Law Review, 1999-2000 |
Professional and Trade
Memberships:
Colorado Bar Association
Denver Bar Association
American Intellectual Property Law Association (AIPLA)
Presentations, Articles,
Publications:
Lee, V.H.L., Traver, R.D., Taub, M., Enzymatic
barriers to peptide and protein drug delivery. In
Peptide and Protein Drug Delivery, V.H.L. Lee ed., Marcel
Dekker, Inc., New York, NY (1991).
Traver, R.D.,
Siegel, D., Heall, H.D., Phillips, R.M., Gibson, N.W., Franklin,
W.A., Ross, D., Characterization of a polymorphism in NAD(P)H:quinone
oxidoreductase (DT-diaphorase). 75 British Journal of Cancer
69-75 (1997).
Kelsey, K.T., Ross, D., Traver,
R.D., Christiani, D.C., Zuo, Z-F., Spitz, M.R., Wang,
M., Xu, X., Lee, B-K., Schwartz, B.S., and Wiencke, J.K.,
Ethnic variation in the prevalence of a common NAD(P)H quinone
oxidoreductase polymorphism and its implications for anti-cancer
chemotherapy, 76 British Journal of Cancer 852-854 (1997).
Rothman, N., Smith, M.T., Hayes,
R.B., Traver R.D., Hoener, B-A., Campleman,
S., Li, G-L., Dosemeci, M., Linet, M., Zhang, L., Xi, L.,
Wacholder, S., Lu, W., Meyer, K.B., Titenko-Holland, N.,
Stewart, J.T., Yin, S., Ross, D., Benzene poisoning, a risk
factor for hematological malignancy, is associated with the
NQO1 609C->T mutation and rapid fractional excretion of
chlorzoxazone, 57 Cancer Research 2839-2842 (1997).
Ross, D., Traver, R.D.,
Siegel, D., Kuehl, B.L., Misra, V., Rauth, A.M., A polymorphism
in NAD(P)H:quinone oxidoreductase (NQO1): relationship of
a homozygous mutation at position 609 of the NQO1 cDNA to
NQO1, 74 British Journal of Cancer 995-6 (1996).
Ross, D., Beall, H.D., Siegel,
D., Traver, R.D., Gustafson, D.L., Enzymology
of bioreductive drug activation, 74 British Journal of Cancer
(Suppl. XXVII) S1-S8 (1996).
Ross, D., Beall, H., Traver,
R.D., Siegel, D., Phillips, R.M., and Gibson, N.W.,
Bioactivation of quinones by DT-diaphorase, molecular, biochemical,
and chemical studies [Review], 6 (10-11) Oncology Research
493-500 (1994).
Traver, R.D.,
Horikoshi, T., Danenberg, K.D., Stadlbauer, T.H.W., Danenberg,
P.V., Ross, D., and Gibson, N.W., NAD(P)H:Quinone oxidoreductase
gene expression in human colon carcinoma cells: characterization
of a mutation which modulates DT-Diaphorase activity and mitomycin
sensitivity, 52 Cancer Research 797-802 (1992).
|
